Abstract: A selection of strains of lactic bacteria and bifidobacteria of human intestinal origin capable of metabolizing oxalates is described. Moreover, a food composition or supplement product or pharmaceutical composition containing said bacterial strains is also described.

Abstract: Selection of probiotic strains belonging to the genus Bifidobacterium and to a symbiotic composition containing the same for use of feeding infants, is described.

Abstract: A composition comprising probiotic bacteria for use in the pharmacological treatment of gastric hyperacidity is described. The composition is capable of restoring the barrier effect of the stomach which is lost during pharmacological treatment of gastric hyperacidity and minimizes the secondary effects due to said pharmacological treatment.

Abstract: The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.

Abstract: The present invention relates to a composition having antioxidant activity. Furthermore, the present invention relates to probiotic bacteria having antioxidant activity and the use thereof.

Abstract: The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.

Abstract: The present invention relates to conjugated linoleic acid (CLA)-producing strains of probiotic bacteria. In particular, the present invention relates to a selection of bacterial strains belonging to the genus Bifidobacterium which were selected for their ability to produce conjugated linoleic acid (CLA) from linoleic acid (LA). Furthermore, the present invention relates to a food, dietetic or pharmaceutical composition comprising said bacterial strains capable of increasing the quantity of CLA in situ, i.e. inside the gastrointestinal tract.

Abstract: The present invention relates to a selected strain of Lactobacillus pentosus for use as a medication for the preventive or curative treatment of infections due to Gram-negative bacteria, preferably enterococci, coliforms and E. coli.

Abstract: The present invention relates to folic acid-producing bacterial strains belonging to the genus Bifidobacterium, pharmaceutical, veterinary or food formulations containing them and the use thereof. In particular, the invention relates to new bacterial strains of human origin belonging to the genus Bifidobacterium, adolescentis species (2), the genus Bifidobacterium, breve species (1) and the genus Bifidobacterium, pseudocatenulatum species (2) deposited in the DSMZ collection center (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH; Braunsweig, Germany), in accordance with the Treaty of Budapest, on 21 Jul. 2004.

Abstract: The present invention relates to probiotic bacteria strains having a high anti-inflammatory activity. The present invention relates to bacteria strains as strongly inducers of Interleukin-10 (IL-10) production. In particular, the present invention relates to the anti-inflammatory activity shown by said bacteria strains due to its enhancement of IL-10 production in peripheral blood mononuclear cells, with on the other hand a low capability to stimulate the production of the pro-inflammatory 11-12, thus leading to a high IL-10/IL-12 ratio. Further, the present invention relates to the use of at least one bacterium strain for the preparation of a composition for the prevention or treatment of the inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS). Finally, the present invention relates to food products, such as probiotic dietary supplements containing at least one probiotic bacterium strain, as an active ingredient.

Abstract: The present invention refers to a food product. In particular, the present invention refers to a form of administration of a high and stable load of probiotic bacteria preferentially to persons of paediatric age. The present invention furthermore refers to a chocolate flavoured probiotic supplement, in particular to a probiotic tablet comprising an inner part, represented by a core of chocolate containing coated probiotic bacteria, and an outer part, represented by an outer coating. In particular, the present invention refers to a form of administration of a high and stable load of probiotic bacteria.

Abstract: The present invention refers to the use of probiotic bacteria for the treatment of hyperhomocysteinaemia. The present invention furthermore refers to a composition comprising probiotic bacteria in association with at least one vitamin chosen from the group comprising the B group of vitamins for the treatment of plasma hyperhomocysteinaemia.

Abstract: The present invention relates to a composition based on probiotic bacteria and a substance having probiotic properties and the use thereof to prevent and/or treat respiratory pathologies and/or infections and simultaneously improve intestinal functionality, which may be compromised by the therapeutic treatments adopted to resolve said pathological conditions.

Abstract: The present invention relates to fermented soymilk and to a method for improving the organoleptic properties of fermented soymilk.

Abstract: The present invention relates to formulations of culture mediums for the industrial development of liquid starter cultures characterized by a larger number of microbial cells per volume unit of fermentation medium than the one of traditional liquid starter cultures, which number can be defined a priori depending on the formulation of said medium.

Abstract: The present invention relates to a method, called Mofinazione process, for preparing a milk intended for milk-dairy applications, the milk obtained with said method and the uses thereof. Said method includes an opportune heat treatment of the milk, followed by a pre-maturation concerning the addition and the development within said milk of opportune bacterial strains selected for this purpose, in particular strains with a probiotic valence.

Abstract: The aim of the present invention is “gluten-free” spore or mildew cultures of the genus Penicillium, in particular of the species Penicillium roqueforti for the blue-veining of cheeses intended for persons affected by celiac disease. Furthermore, the aim of the present invention is a method for the preparation of said cultures which foresees the use of an anallergic substrate in association with a subsequent enzymatic treatment.

Abstract: The aim of the present invention is a method for the preparation of anallergic probiotic bacterial cultures.

Abstract: The present invention relates to folic acid-producing bacterial strains belonging to the genus Bifidobacterium, pharmaceutical, veterinary or food formulations containing them and the use thereof. In particular, the invention relates to new bacterial strains of human origin belonging to the genus Bifidobacterium, adolescentis species (2), the genus Bifidobacterium, breve species (1) and the genus Bifidobacterium, pseudocatenulatum species (2) deposited in the DSMZ collection center (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH; Braunsweig, Germany), in accordance with the Treaty of Budapest, on 21 Jul. 2004.

Abstract: The object of the present invention is a probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the contemporaneous improvement of the intestinal functionality, which can be compromised by therapeutic treatments adopted for re-solving said pathological conditions. Besides that, aim of this invention is a probiotic bacteria-based composition comprising moreover a suitable quantity of at least a substance or nourishment having prebiotic properties and eventually, of suitable pharmacologically active substances.